Annexon (ANNX) Share-based Compensation (2019 - 2026)
Annexon's (ANNX) quarterly Share-based Compensation came in at $11.5 million in Q1 2026, up 126.47% year-on-year from $5.1 million in Q1 2025, and up 247.96% quarter-over-quarter from $3.3 million in Q4 2025.
Annexon (ANNX) Share-based Compensation (2019 - 2026) Analysis & Trends
Annexon's Share-based Compensation history runs 8 years deep, the most recent figure standing at $11.5 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 126.47% year-over-year to $11.5 million in Q1 2026; TTM through Mar 2026 was $11.5 million, a 42.07% decrease from a year earlier, with the FY2025 full-year figure at $24.5 million, up 26.07% from the prior year.
- Share-based Compensation rose to $11.5 million in Q1 2026 per ANNX's latest filing, from $3.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.5 million in Q1 2026 and bottomed at $3.3 million in Q4 2025.
- The 5-year median for Share-based Compensation is $4.6 million (2024), against an average of $4.9 million.
- Across the five-year window, Share-based Compensation slumped 36.71% in 2025 and jumped 126.47% in 2026, its largest moves.
- Year by year, Share-based Compensation stood at $4.8 million in 2022, then decreased by 9.64% to $4.4 million in 2023, then advanced by 19.58% to $5.2 million in 2024, then slumped by 36.71% to $3.3 million in 2025, then soared by 247.96% to $11.5 million in 2026.
- Per Business Quant, the three latest ANNX Share-based Compensation figures stand at $11.5 million (Q1 2026), $3.3 million (Q4 2025), and $3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Annexon | 1.03 Bn | 804.24 Mn | - | 11.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.50 Mn |
| Mar 31, 2026 | 11.50 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Dec 31, 2023 | 4.37 Mn |